[HTML][HTML] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - European Journal of Medical Research, 2023 - Springer
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
[HTML][HTML] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - … Journal of Medical …, 2023 - eurjmedres.biomedcentral.com
Previous studies showed that the combination of bevacizumab and erlotinib (combination
therapy) significantly prolonged progression-free survival (PFS) but no overall survival (OS) …
therapy) significantly prolonged progression-free survival (PFS) but no overall survival (OS) …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
R Li, W Li, F Zhang, S Li - European Journal of Medical …, 2023 - search.ebscohost.com
Objective: Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - European journal of medical …, 2023 - pubmed.ncbi.nlm.nih.gov
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
R Li, W Li, F Zhang, S Li - European Journal of Medical Research, 2023 - go.gale.com
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - European Journal of Medical …, 2023 - search.proquest.com
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
R Li, W Li, F Zhang, S Li - European Journal of Medical Research, 2023 - europepmc.org
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
[HTML][HTML] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - European Journal of Medical Research, 2023 - ncbi.nlm.nih.gov
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
[PDF][PDF] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - 2023 - eurjmedres.biomedcentral.com
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
[引用][C] Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
R Li, W Li, F Zhang, S Li - 2023 - europepmc.org
Objective Previous studies showed that the combination of bevacizumab and erlotinib
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …
(combination therapy) significantly prolonged progression-free survival (PFS) but no overall …